|Day Low/High||2.63 / 2.75|
|52 Wk Low/High||1.99 / 5.05|
We rang the register on part of a high-flying position and added to another on weakness.
With the small-cap heavy Russell 2000 leading the major market index pack last week, we saw a number of pronounced moves higher in the portfolio.
REDWOOD CITY, Calif., Feb.
Another melt-up for the stock market, together with a late-Friday surge was a positive for several portfolio holdings.
We closed our position in Fitbit for a healthy profit and added twice to USA Technologies last week.
We booked hefty wins last week exiting Blue Apron and GE and trimming our position in Fitbit.
While the overall stock market finished last week essentially unchanged, the portfolio had several outperformers.
Investors in AcelRx Pharmaceuticals Inc saw new options become available this week, for the September 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
We added one new position and doubled down on another during a very good week for the portfolio.
We exited two positions last week as the portfolio and the market started off the year in the green.
Investors in AcelRx Pharmaceuticals Inc saw new options become available this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACRX options chain for the new February 15th contracts and identified the following put contract of particular interest.
Despite steep declines in the broader market last week, the portfolio had several winners and was helped by our large cash position.
We added to two positions last week, as positive action in the market led the Russell 2000 to climb.
Given the market pressures of last week, there was little room to hide as the gut punches continued to hit small-cap and technology stocks.
Despite swimming against the recent tide with small-cap stocks, we have several positions that are more than holding their own.
We are not adding to our AcelRx position on this weakness, despite believing in the underlying story, until we have more information.
While health care holdings may suffer, cannabis-related holdings should get a boost.
We saw a number of our positions rebound along with the market last week.
Here’s when we would consider adding to Aurora Cannabis.
Investors in AcelRx Pharmaceuticals Inc saw new options become available this week, for the June 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Amid volatile market activity, we added to four positions last week.
We are buying more shares of AcelRx Pharmaceuticals following an FDA advisory committee’s approval of its NDA candidate.
The majority of our positions outperformed our benchmark during a challenging week for the stock market.
In trading on Monday, shares of AcelRx Pharmaceuticals Inc touched a new 52-week high of $5.03/share. That's a 224.52% rise, or $3.48 per share from the 52-week low of $1.55 set back on 10/19/2017.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.